Zions Bancorporation N.A. Has $9.69 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

Zions Bancorporation N.A. lifted its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.8% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 115,611 shares of the biopharmaceutical company's stock after purchasing an additional 7,331 shares during the period. Gilead Sciences comprises about 0.7% of Zions Bancorporation N.A.'s investment portfolio, making the stock its 15th largest position. Zions Bancorporation N.A.'s holdings in Gilead Sciences were worth $9,693,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in the stock. Manning & Napier Advisors LLC acquired a new stake in shares of Gilead Sciences during the 2nd quarter worth approximately $25,328,000. Legal & General Group Plc boosted its holdings in Gilead Sciences by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 12,414,268 shares of the biopharmaceutical company's stock valued at $851,743,000 after purchasing an additional 93,068 shares during the last quarter. IRON Financial LLC purchased a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $830,000. Wealth Enhancement Advisory Services LLC increased its holdings in shares of Gilead Sciences by 13.1% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 286,116 shares of the biopharmaceutical company's stock worth $19,630,000 after buying an additional 33,162 shares during the last quarter. Finally, Cetera Investment Advisers raised its position in shares of Gilead Sciences by 127.6% during the 1st quarter. Cetera Investment Advisers now owns 213,901 shares of the biopharmaceutical company's stock valued at $15,668,000 after buying an additional 119,909 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

GILD has been the topic of several recent analyst reports. Truist Financial upped their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a "hold" rating in a research note on Friday, November 8th. BMO Capital Markets increased their price target on Gilead Sciences from $94.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, November 7th. Leerink Partnrs upgraded Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. Robert W. Baird increased their price target on Gilead Sciences from $80.00 to $95.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Finally, Cantor Fitzgerald increased their price target on Gilead Sciences from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have issued a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus target price of $93.10.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 29,357 shares of the firm's stock in a transaction on Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the sale, the insider now owns 78,127 shares of the company's stock, valued at $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. In related news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $83.83, for a total transaction of $167,660.00. Following the sale, the insider now directly owns 100,189 shares of the company's stock, valued at $8,398,843.87. This trade represents a 1.96 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The stock was sold at an average price of $83.78, for a total value of $2,459,529.46. Following the sale, the insider now directly owns 78,127 shares in the company, valued at approximately $6,545,480.06. This trade represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock valued at $4,968,674 over the last quarter. Company insiders own 0.16% of the company's stock.

Gilead Sciences Trading Down 0.6 %

NASDAQ:GILD traded down $0.52 on Thursday, hitting $92.11. 7,974,774 shares of the stock were exchanged, compared to its average volume of 7,081,716. The stock has a market cap of $114.68 billion, a PE ratio of 1,029.22, a PEG ratio of 2.91 and a beta of 0.17. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90. The company has a current ratio of 1.11, a quick ratio of 0.82 and a debt-to-equity ratio of 1.18. The stock has a fifty day moving average of $86.22 and a 200-day moving average of $75.69.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. During the same period in the prior year, the firm earned $2.29 EPS. The business's quarterly revenue was up 7.0% on a year-over-year basis. As a group, equities analysts expect that Gilead Sciences, Inc. will post 4.39 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, December 30th. Stockholders of record on Friday, December 13th will be paid a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a dividend yield of 3.34%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's dividend payout ratio is presently 3,422.22%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.